← Back to Search

Topical Cream

EB01 Cream 2.0% for Rash

Phase 2
Waitlist Available
Research Sponsored by Edesa Biotech Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up to day 36, and for open-label extension to day 119

Summary

This trial will test a new cream to see if it is safe and effective in treating people with a chronic allergic skin condition.

Eligible Conditions
  • Rash

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~to day 36, and for open-label extension to day 119
This trial's timeline: 3 weeks for screening, Varies for treatment, and to day 36, and for open-label extension to day 119 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Other study objectives
Tolerability assessed using a numerical rating scale
Treatment-emergent adverse events (TEAEs)

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: EB01 Cream 2.0%Experimental Treatment1 Intervention
EB01 Cream containing 2.0% EB01 w/w applied BID
Group II: EB01 Cream 1.0%Experimental Treatment1 Intervention
EB01 Cream containing 1.0% EB01 w/w applied BID
Group III: EB01 Cream 0.2%Experimental Treatment1 Intervention
EB01 Cream containing 0.2% EB01 w/w applied BID
Group IV: EB01 Cream PlaceboActive Control1 Intervention
EB01 Cream containing 0% EB01 w/w applied BID

Find a Location

Who is running the clinical trial?

JSS Medical Research Inc.Industry Sponsor
18 Previous Clinical Trials
5,369 Total Patients Enrolled
Edesa Biotech Inc.Lead Sponsor
1 Previous Clinical Trials
644 Total Patients Enrolled
~21 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top